AstraZeneca announced that the EC green-lighted the new formulation of the once-weekly type-2 diabetes injection, which will be marketed as Bydureon BCise (exenatide 2mg prolonged-release suspension).

No evidence seen to support GLP-1 receptor agonist exenatide as disease-modifying ... extended-release exenatide 2 mg by subcutaneous pen injection once per week over 96 weeks or visually ...

BYDUREON BCise (exenatide extended-release ... It comes in an auto-injector pen with a pre-attached, hidden needle that doesn't need to be handled or seen. Mounjaro may cause tumors in the ...

The recommended dosage of Bydureon weight loss is 2 mg injected subcutaneously (under the skin) once a week. Bydureon comes in a single-use pen device that is pre-filled with the medication. Su Tang ...

For instance, individuals with type 1 diabetes require more precise insulin dosing and may benefit from short-acting glucagon-like peptide (GLP)-1 receptor agonists like exenatide for enhanced ... In ...

Objective–To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. Research Design ...

AstraZeneca has had a setback to its ambitions in diabetes, after Bydureon failed to show cardiovascular benefits to patients. The FDA now obliges companies with diabetes products to conduct large ...

This product could take off in 2025, as it is cheaper ($69/month for a 10-month plan) than Novo Nordisk's Wegovy ($1,349.02/package) and Ozempic ($997.58 for 1x3mL pen). I know what most readers ...

There are quite a few stylus apps available on the Play Store. Let’s take a look at the best stylus apps and S Pen apps for Android. The Adobe family has excellent apps for using a stylus.

Management provided a revenue guidance range of $1.34 billion to $1.36 billion for 2025, with gross margins expected to exceed 67% for the full year. Operating margins are forecasted to expand to ...